Filter by
Format
All
Sort by
Newest

Metabolic

  • Jardiance
  • Synjardy
  • Heart Failure
/za/metabolic/jardiance/proven-efficacy/emperor-reduced-clinical-trial-summary

EMPEROR-Reduced Clinical Trial Summary
/za/metabolic/jardiance/proven-efficacy/emperor-preserved-clinical-trial-summary

EMPEROR-Preserved Clinical Trial Summary
/za/metabolic/jardiance/efficacy/value-time-45-years

3:00

Value of Time - 4.5 years
/za/metabolic/jardiance/reimbursement-information/value-co-pay-test-need-to-delete-not-in-seo

4:01
Value of Co-pay
/za/metabolic/jardiance/efficacy/value-time-25-years-test-need-to-delete-not-in-seo

3:05

Value of Time -2.5 years
/za/metabolic/jardiance/reimbursement-information/budget-impact-analysis-empagliflozin-treatment-patients-type-2-diabetes-test-need-to-delete-not-in-seo

Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa
/za/metabolic/jardiance/reimbursement-information/what-are-overarching-takeaway-messages-budget-impact-empagliflozin

1:24

What are the overarching takeaway messages from the Budget Impact of Empagliflozin in the Treatment of Patients with T2D with eCVD in South Africa?
/za/metabolic/jardiance/reimbursement-information/where-should-hcps-position-snjardy-treatment-t2d-and-its-complications-test-need-to-delete-not-in-seo

0:59
Where should HCPs position Synjardy in the treatment of T2D and its complications?
/za/metabolic/jardiance/reimbursement-information/which-patients-should-clincians-be-targeting-empagliflozin-use-test-need-to-delete-not-in-seo

1:04
Which patients should clinicians be targeting for Empagliflozin use
/za/metabolic/jardiance/reimbursement-information/it-fair-reimbursement-solely-based-cost-when-studies-budget-impact-test-need-to-delete-not-in-seo

1:46
Is it fair that reimbursement is solely based on cost when studies like the Budget Impact of Empagliflozin demonstrate that other parameters should be guiding reimbursement decisions?
/za/metabolic/jardiance/reimbursement-information/should-empagliflozin-have-more-favorable-position-upcoming-guidelines

1:03
Should Empagliflozin have a more favorable position in upcoming guidelines?
/za/metabolic/jardiance/reimbursement-information/why-are-nnts-extrapolated-empa-reg-trial-consisdered-impressive

1:34
Why are the NNTs extrapolated from the EMPA-REG Trial considered impressive?
/za/metabolic/jardiance/reimbursement-information/can-outcomes-budget-impact-study-be-extraploated-sglt2-i-class-or-are

1:02
Can the outcomes of the Budget Impact study be extrapolated to SGLT2-I class? Or are they Empagliflozin specific, if so why?
/za/metabolic/jardiance/reimbursement-information/what-budget-impact-study-empaglflozin-about-and-why-was-it-conducted

1:02
What is the Budget Impact study of Empagliflozin about and why was it conducted?
/za/metabolic/jardiance/reimbursement-information/budget-impact-empagliflozin-treatment-patients-t2d-ecvd-south-africa-test-need-to-delete-not-in-seo

10:50
Budget Impact of Empagliflozin in the Treatment of Patients with T2D with eCVD in South Africa
/za/metabolic/jardiance/efficacy/look-beyond-metabolic-control-test-need-to-delete-not-in-seo

Look Beyond Metabolic Control
/za/metabolic/jardiance/efficacy/jardiance-cardio-renal-benefits

Jardiance Cardio-Renal Benefits
/za/metabolic/jardiance/efficacy/risks-t2d

1:07
The Risks of T2D
/za/metabolic/jardiance/tools-and-guidelines/abcdes-diabetes-care-test-need-to-delete-not-in-seo

ABCDES of Diabetes Care
/za/metabolic/jardiance/efficacy/empa-animation-empa-reg-emprise-test-need-to-delete-not-in-seo

3:24
The journey of EMPA from RCT to RWE
/za/metabolic/jardiance/efficacy/embark-now-gain-more-test-need-to-delete-not-in-seo

1:12
EMPA when time MEETS power
/za/metabolic/jardiance/efficacy/empa-reg-benefits-video

1:37
EMPA REG animation Video
/za/metabolic/synjardy/dosing-administration/synjardy-comparison-met-ddp4is

Synjardy Comparison with MET + DDP4is
/za/metabolic/jardiance/efficacy/cv-reduction-was-generally-consistent-across-baseline-hba1c-test-need-to-delete-not-in-seo

0.58
CV Reduction was generally consistent across baseline HbA1c
/za/metabolic/jardiance/efficacy/patients-could-live-longer-jardiance-test-need-to-delete-not-in-seo

0.59
Patients could live longer with Jardiance
/za/metabolic/jardiance/efficacy/relative-risk-reduction-cv-death-more-13-test-need-to-delete-not-in-seo

1:01
Relative risk reduction of CV death by more than 1/3
/za/metabolic/jardiance/efficacy/early-impact-risk-reduction-cv-death-test-need-to-delete-not-in-seo

1:01
Early impact on risk reduction of CV death
/za/metabolic/jardiance/efficacy/reduction-cv-death-was-achieved-ontop-standard-care-test-need-to-delete-not-in-seo

1:03
Reduction of CV death was achieved ontop of standard of care
/za/metabolic/synjardy/efficacy/battle-fixed-dose-combinations-test-need-to-delete-not-in-seo

Battle of The Fixed Dose Combinations
/za/metabolic/synjardy/efficacy/simplicity-efficacy-and-protetion-1-product

Simplicity, Efficacy and Protetion in 1 product
/za/metabolic/synjardy/efficacy/think-heart-your-t2d-patients

Think of the Heart in your T2D patients
/za/metabolic/synjardy/convenience/convenience-jardiance-and-metformin-one-tablet

THE CONVENIENCE OF JARDIANCE® AND METFORMIN IN ONE TABLET
/za/metabolic/synjardy/efficacy/synjardy-vs-other-ddp4-inhibitors-test-need-to-delete-not-in-seo

Synjardy vs other DDP4 Inhibitors
/za/metabolic/heart-failure/jardiance-hf/heart-failure-mass-launch-letter-test-need-to-delete-not-in-seo

Heart Failure Mass Launch Letter
/za/metabolic/heart-failure/jardiance-hf/heart-failure-gp-launch-leave-behind-test-need-to-delete-not-in-seo

Heart Failure GP Launch Leave Behind
/za/metabolic/heart-failure/jardiance-hf/heart-failure-launch-leave-behind-test-need-to-delete-not-in-seo

Heart Failure Launch Leave Behind

Cardiovascular

  • Actilyse
/za/cardiovascular/actilyse/mode-action/mode-action-video-test-need-to-delete-not-in-seo

1:53

mode of Action of Actilyse
/za/cardiovascular/actilyse/treatment/acute-stroke-management-test-need-to-delete-not-in-seo

Acute stroke management is an emergency
/za/cardiovascular/actilyse/safety-efficac/ecass-3-safety-endpoints-mortality-itt1-test-need-to-delete-not-in-seo

ECASS 3* Safety Endpoints
/za/cardiovascular/actilyse/safety-efficacy/actilyse-improved-clinical-outcome-test-need-to-delete-not-in-seo

Actilyse Improved Clinical Outcomes
/za/cardiovascular/actilyse/safety-efficacy/ecass3-effective-treatment-ais-45-hours-after-symptom-onset

ECASS 3* Effective Treatment For AIS
/za/cardiovascular/actilyse/treatment/rt-pa-bridging-with-thrombectomy-test-need-to-delete-not-in-seo

rt-PA bridging with Thrombectomy
/za/cardiovascular/actilyse/treatment/acute-stroke-management-tips-test-need-to-delete-not-in-seo

Acute Stroke management tips
/za/cardiovascular/actilyse/treatment/rt-pa-bridging-thrombectomy-acute-stroke-management-test-need-to-delete-not-in-seo

rt-PA bridging with Thrombectomy for Acute Stroke Management

Respiratory

  • OFEV
/za/respiratory/ofev/disease-state/fvc-decline-across-ilds-test-need-to-delete-not-in-seo

49:14
Antifibrotic treatment
/za/respiratory/ofev/disease-state/new-indications-test-need-to-delete-not-in-seo

43:38
IPF
/za/respiratory/ofev/disease-state/patients-affected-ild-test-need-to-delete-not-in-seo

38:27
Recognise and diagnose
/za/respiratory/ofev/beyond-fvc/expanding-horizons-differentiated-value-ofev-test-need-to-delete-not-in-seo

Acute exacerbation of ILD is a deadly threat
/za/respiratory/ofev/confidence-numbers/broad-ild-patient-base-can-benefit-test-need-to-delete-not-in-seo

Clinical experience across multiple trials (Pulmos 2)
/za/respiratory/ofev/confidence-numbers/progression-waits-no-one-test-need-to-delete-not-in-seo

Progression waits for no one
/za/respiratory/ofev/disease-state/pf-common-enemy-pulmos-2-test-need-to-delete-not-in-seo

PF is a common enemy (Pulmos 2)
/za/respiratory/ofev/efficacy/broadly-indicated-test-need-to-delete-not-in-seo

1:45
Expanding the ability to treat
/za/respiratory/ofev/disease-state/who-treat-eligible-patients-across-ctd-ilds-test-need-to-delete-not-in-seo

ILD Progression across CTD patients
/za/respiratory/ofev/confidence-numbers/a-common-enemy-test-need-to-delete-not-in-seo

A common threat to SSc and CTD patients
/za/respiratory/ofev/confidence-numbers/meaningful-data-across-a-broad-range-of-patients-test-need-to-delete-not-in-seo

A broad range of SSc-ILD patients
/za/respiratory/ofev/wide-range-ilds/common-enemy-impact-ilds-test-need-to-delete-not-in-seo

Risk of progression
/za/respiratory/ofev/confidence-numbers/broad-range-of-ild-patients-test-need-to-delete-not-in-seo

Clinical experience across multiple trials
/za/respiratory/ofev/disease-state/broad-range-ild-patient-base-can-benefit-test-need-to-delete-not-in-seo

Abroad patient base
/za/respiratory/ofev/beyond-fvc/expanding-horizons-with-then-differentiated-value-of-ofev-test-need-to-delete-not-in-seo

Exacerbation Risk
/za/respiratory/ofev/disease-state/common-threat-pulmonary-fibrosis-test-need-to-delete-not-in-seo

Who to treat?
/za/respiratory/ofev/efficacy/ssc-ild-skin-lung-scencis-implications-1-test-need-to-delete-not-in-seo

25:42
SSc-ILD: From Skin to lung. The Scencis implications
/za/respiratory/ofev/efficacy/slow-progression-pf-ild

Slow Progression PF-ILD
/za/respiratory/ofev/beyond-fvc/nightmare-called-exacerbations-test-need-to-delete-not-in-seo

A nightmare called Exacerbations
/za/respiratory/ofev/treatment-diagnosis/when-its-more-cough-3

When it is more than a cough 3
/za/respiratory/ofev/treatment-diagnosis/when-its-more-cough-2

When it is more than a cough 2
/za/respiratory/ofev/beyond-fvc/life-worth-living-3

Life is worth Living 3
/za/respiratory/ofev/treatment-diagnosis/when-its-more-cough-1

When it is more than a cough 1
/za/respiratory/ofev/beyond-fvc/life-worth-living-2-test-need-to-delete-not-in-seo

Life is worth living 2
/za/respiratory/ofev/beyond-fvc/life-worth-living-1

Life is worth Living 1
/za/respiratory/ofev/treatment-diagnosis/ipf-prevalence-and-diagnosis-challenges-test-need-to-delete-not-in-seo

24:37
IPF prevalence and diagnosis challenges